AtriCure, Inc. (ATRC) Launches Three-Year Post-Approval Study for the Surgical Correction of Atrial Fibrillation
9/13/2012 10:35:28 AM
WEST CHESTER, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (NASDAQ: ATRC), the leader in surgical ablation for the treatment of Atrial Fibrillation, has announced FDA approval of the ABLATE Post Approval Study (PAS). This landmark three-year, 350 patient study is a follow-up to the company’s December 14, 2011 FDA approval of the AtriCure Synergy Ablation System for the surgical treatment of Atrial Fibrillation (AF). AtriCure is the first and only surgical company with a specific, on label indication for AF. The PAS study is intended to build additional evidence on the safety, efficacy and long-term durability of the Maze IV concomitant treatment for AF using AtriCure’s proprietary surgical devices.